Back to Top
Go Back
Journal Photo for Vaccine
Peer reviewed only Open Access

Vaccine (Vaccine)

Publisher : Elsevier Ltd.
Immunology Microbiology Virology
e-ISSN 1873-2518
p-ISSN 0264-410X
Issue Frequency Monthly
Impact Factor 4.5
Est. Year 1983
Mobile 31204853911
Country Netherlands The
Language English
APC YES
Impact Factor Assignee Google Scholar
Email angela.rasmussen@usask.ca

Journal Descriptions

The official journal of The Japanese Society for Vaccinology. Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions. We also invite authors to submit relevant basic science and clinical reviews, methodological articles, opinion and commentary pieces, visual pieces, and letters. Authors are required to consult the Guide for Authors as the submission guidelines are dynamic and therefore subject to change. Vaccine has an open access companion journal titled Vaccine: X. The Editors retain the right to desk reject submissions without peer review when it is clear that the Guide for Authors has not been consulted.

Vaccine (Vaccine) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Immunology, Microbiology, Virology, Allergology and Rheumatology, Infectious Diseases, Public Health and Health Policy, Veterinary Medicine, Veterinary Science , Online or Print , Monthly Journal

  • UGC Approved, ISSN Approved: P-ISSN P-ISSN: 0264-410X, E-ISSN: 1873-2518, Established: 1983, Impact Factor: 4.5
  • Does Not Provide Crossref DOI
  • Indexed in: Scopus, WoS, DOAJ, PubMed

  • Not indexed in UGC CARE

Indexing

Publications of Vaccine

Introduction Human papillomavirus (HPV) vaccine trials have demonstrated high efficacy in preventing HPV infections and HPV related disease in females ages 16–26. However, there is no sou...
James Dennis Fortenberry October, 2013
Objectives Because little is known about the content of human papillomavirus (HPV) vaccine-related discussions with young adolescent girls in clinical settings, we explored communication be...